Blocking of NKG2DL receptor shows decrease in BI 836858 ADCC in post-DAC samples. (A) Surface expression of NKG2DL in patients who received DAC. The dark histograms show expression of MICA, ULBP-1, ULBP-2, and ULBP-3 at baseline, and the gray histograms show expression on day 28 post-DAC. (B) Blocking of surface expression of NKG2DL shows decrease in BI 836858–mediated ADCC in post-DAC samples. Surface expression of ULBP-3 was blocked in day 1 and day 28 samples. BI 836858–mediated ADCC was lower is samples where ULBP-3 was blocked.